Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5202366
Max Phase: Preclinical
Molecular Formula: C44H53FN8O6S
Molecular Weight: 841.02
Associated Items:
ID: ALA5202366
Max Phase: Preclinical
Molecular Formula: C44H53FN8O6S
Molecular Weight: 841.02
Associated Items:
Canonical SMILES: CCN(CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C)CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(-c2scnc2C)cc1)C(C)(C)C
Standard InChI: InChI=1S/C44H53FN8O6S/c1-8-52(16-15-46-42(58)37-24(2)34(49-25(37)3)19-32-31-17-29(45)13-14-33(31)50-40(32)56)22-36(55)51-39(44(5,6)7)43(59)53-21-30(54)18-35(53)41(57)47-20-27-9-11-28(12-10-27)38-26(4)48-23-60-38/h9-14,17,19,23,30,35,39,49,54H,8,15-16,18,20-22H2,1-7H3,(H,46,58)(H,47,57)(H,50,56)(H,51,55)/b32-19-/t30-,35+,39-/m1/s1
Standard InChI Key: FEBZDTYMYVJAEP-XHQJFUIVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 841.02 | Molecular Weight (Monoisotopic): 840.3793 | AlogP: 4.56 | #Rotatable Bonds: 14 |
Polar Surface Area: 188.86 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.39 | CX Basic pKa: 6.74 | CX LogP: 2.94 | CX LogD: 2.86 |
Aromatic Rings: 4 | Heavy Atoms: 60 | QED Weighted: 0.10 | Np Likeness Score: -0.92 |
1. Zhai J, Li C, Sun B, Wang S, Cui Y, Gao Q, Sang F.. (2022) Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines., 78 [PMID:36332882] [10.1016/j.bmcl.2022.129041] |
Source(1):